
|Articles|September 1, 2003
Expensive or Good Deal?
Biologics manufacturers cite complex research and development process,along with FDA scrutiny, as reason for costly - but worthy - drugs
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
KT-621 Produces 98% STAT6 Degradation in AD Patients
3
Transparency Gaps in Prior Authorization Denials and Their Impact on Dermatologic Care
4
Abeona Initiates First Commercial Treatment of Zevaskyn for RDEB
5



















